Figure 3: Detection of residual disease using computed tomography (CT) imaging and ctDNA analyses. | Nature Communications

Figure 3: Detection of residual disease using computed tomography (CT) imaging and ctDNA analyses.

From: Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Figure 3

(a) Patients with detectable ctDNA after surgical resection (n=10) were more likely to relapse and die from disease compared with those with undetectable ctDNA (n=10). The median time to recurrence as determined by CT imaging was 9.9 months for individuals with detectable ctDNA and was not reached for those without detectable ctDNA (P=0.0199, log-rank). (b) Comparison between the time to detection of recurrence using ctDNA and standard-of-care CT imaging revealed that the average time to recurrence was 3.1 months for individuals with detectable ctDNA and 9.6 months for those patients with positive imaging results (n=9, P=0.0004, paired t-test).

Back to article page